科研成果
科研项目：
1. 2023-10 至 2026-12 消化系统恶性肿瘤中西医结合诊治 KJ-2023-103 横向课题 在研主持20万
2. 2022-01 至 2024-12 zDHHC9对免疫检查点抑制剂的疗效预测作用研究 YKK21199 一般性课题 在研主持 南京市卫健委 3万元
3. 2024-2026 呋喹替尼联合TAS-102及信迪利单抗在难治性晚期结直肠癌的一项单臂，前瞻性，探索性临床研究 HX20241112-（吴阶平医学基金）5万元
4. PT20240408-2024年度江苏省基础研究专项资金（自然科学基金）配套项目 10万元
近五年发表论文：
1) 王坤;邵驰运;李京波;周莹莹;邵悦灵;方明治;李敏.基于阳遏阴积病机探析结直肠癌辨证论治 [J/OL]. 环球中医药, 1-6[2025-01-04]. http://kns.cnki.net/kcms/detail/11.5652.R.20240911.1755.004.html.
2) Zhang Z, Li M, Zhang X, Zhou F. Novel Strategies for Tumor Treatment: Harnessing ROS-Inducing Active Ingredients from Traditional Chinese Medicine Through Multifunctional Nanoformulations. Int J Nanomedicine. 2024;19:9659-9688.
3) Zhang Z, Lu T, Zhang Z, Liu Z, Qian R, Qi R, Zhou F, Li M. Unraveling the immune landscape and therapeutic biomarker PMEPA1 for oxaliplatin resistance in colorectal cancer: A comprehensive approach. Biochem Pharmacol. 2024 Mar 8;222:116117.
4) Han YJ, Shao CY, Yao Y, Zhang Z, Fang MZ, Gong T, Zhang YJ, Li M. Immunotherapy of microsatellite stable colorectal cancer: resistance mechanisms and treatment strategies. Postgrad Med J. 2024 Jan 11:qgad136.
5) Shao C, Han Y, Huang Y, Zhang Z, Gong T, Zhang Y, Tian X, Fang M, Han X, Li M. Targeting key RNA methylation enzymes to improve the outcome of colorectal cancer chemotherapy (Review). Int J Oncol. 2024 ;64(2):17.
6) 邵驰运,方明治,贡涛,李敏.方明治教授基于“虚气留滞”理论辨治肺癌相关性厌食经验[J].山西中医药大学学报,2023,24(11):1236-1239+1243.
7) Liao C, Li M（#）, Chen X, Tang C, Quan J, Bode AM, Cao Y, Luo X. Anoikis resistance and immune escape mediated by Epstein-Barr virus-encoded latent membrane protein 1-induced stabilization of PGC-1α promotes invasion and metastasis of nasopharyngeal carcinoma. J Exp Clin Cancer Res. 2023;42(1):261.
8) 杨丹,李敏,方明治.从癌症中医治疗原则浅析中药逆转结直肠癌多药耐药性[J/OL].实用中医内科杂志,1-4[2023-12-31
9) 黄钰莹,方明治,李敏.肿瘤相关成纤维细胞介导免疫治疗耐药的机制研究[J].肿瘤预防与治疗,2023,36(10):900-907.
10) Gong T, Li Y, Feng L, Xu Q, Dai G, Li M, Wang Y, Liu S. SNHG25 promotes colorectal cancer metastasis by regulating MMP2. Aging (Albany NY). 2023 Sep 25;15(19):10105-10116.
11) Li M, Xia M, Zhang Z, Tan Y, Li E, Guo Z, Fang M, Zhu Y, Hu Z. METTL3 antagonizes 5 FU chemotherapy and confers drug resistance in colorectal carcinoma. Int J Oncol. 2022 Sep;61(3):5396.
12) Liu P, Jiao F, Zhang Z, Zhao F, Cai J, Chen S, Fu T, Li M（通讯）. Identification of BIK as an unfavorable prognostic marker and novel therapeutic target in microsatellite stable colorectal cancer harboring KRAS mutations. Am J Cancer Res. 2022;12(11):5300-5314.
13) Du H, Xu D, Zhang S, Zhang X, Fang M, Li M（通讯）. Adenocarcinoma arising in an ectopic enterogenous cyst: A rare case report and review of literature. Front Oncol. 2022;12:942449.
14) Yang A, Li M(*通讯), Fang M. The Research Progress of Direct KRAS G12C Mutation Inhibitors. Pathol Oncol Res. 2021;27:631095.
15) 刘明顺,方明治,李敏（通讯）.结直肠癌靶向药物耐药机制研究进展[J].现代肿瘤医学,2021,29(15):2730-2735.
16) Lu, Yiyu; Zhou, Chungen; Zhu, Meidong; Fu, Zhiliang; Shi, Yong; Li, Min; Wang, Wenhai; Zh u, Shibo; Jiang, Bin; Luo, Yunquan; Su, Shibing ; Traditional chinese medicine syndromes classifi cation associates with tumor cell and microenvironment heterogeneity in colorectal cancer: a sing le cell RNA sequencing analysis., Chinese Medicine, 2021, 16(1): 133
杨爱,方明治,李敏（通讯）.中药治疗手足综合征的研究进展[J].中医药导报,2020,26(11):86-88+92.